Table 1 The relationship between high- and low- expression of SAAL1 and clinical characteristics of LAC patients

N

267

268

T stage

0.007

 T1

101 (19%)

74 (13.9%)

 T2

124 (23.3%)

165 (31%)

 T3

29 (5.5%)

20 (3.8%)

 T4

11 (2.1%)

8 (1.5%)

N stage

0.339

 N0

178 (34.3%)

170 (32.8%)

 N1

49 (9.4%)

46 (8.9%)

 N2

32 (6.2%)

42 (8.1%)

 N3

0 (0%)

2 (0.4%)

M stage

0.679

 M0

179 (46.4%)

182 (47.2%)

 M1

14 (3.6%)

11 (2.8%)

Pathologic stage

0.200

 Stage I

147 (27.9%)

147 (27.9%)

 Stage II

67 (12.7%)

56 (10.6%)

 Stage III

34 (6.5%)

50 (9.5%)

 Stage IV

15 (2.8%)

11 (2.1%)

Primary therapy outcome

0.212

 PD

30 (6.7%)

41 (9.2%)

 SD

17 (3.8%)

20 (4.5%)

 PR

5 (1.1%)

1 (0.2%)

 CR

168 (37.7%)

164 (36.8%)

Gender

0.631

 Female

146 (27.3%)

140 (26.2%)

 Male

121 (22.6%)

128 (23.9%)

Race

0.146

 Asian

6 (1.3%)

1 (0.2%)

 Black or African American

25 (5.3%)

30 (6.4%)

 White

199 (42.5%)

207 (44.2%)

Age

0.596

 <  = 65

123 (23.8%)

132 (25.6%)

 > 65

133 (25.8%)

128 (24.8%)

Anatomic neoplasm subdivision

0.142

 Left

110 (21.2%)

95 (18.3%)

 Right

147 (28.3%)

168 (32.3%)

Smoker

0.630

 No

40 (7.7%)

35 (6.7%)

 Yes

221 (42.4%)

225 (43.2%)

OS event

0.003

 Alive

188 (35.1%)

155 (29%)

 Dead

79 (14.8%)

113 (21.1%)

DSS event

 < 0.001

 Alive

205 (41.1%)

174 (34.9%)

 Dead

43 (8.6%)

77 (15.4%)

PFI event

0.007

 Alive

170 (31.8%)

139 (26%)

 Dead

97 (18.1%)

129 (24.1%)